CBD has solid evidence for rare pediatric epilepsies, preliminary signal in anxiety and psychosis, and insufficient evidence for most conditions it’s marketed for.
Trauma reminders trigger substance craving — but the path runs through negative emotions, not directly. A 2026 meta-analysis quantifies the link.
Global age-standardized substance-use-disorder rates fell 16.9% from 1990–2021. High-income North America rose 24%—the divergence US coverage misses.
ABCD’s 11,036-youth study finds flattened cognitive trajectories in teen cannabis users, not absolute decline. THC drives the signal; CBD doesn’t.
AVATAR therapy ties CBT at end of treatment, edges ahead at 3-month follow-up, and uses half the sessions. The ‘better than CBT’ framing outpaces the formal statistics.
Loneliness raises measured risk of Alzheimer’s, suicidal ideation, and completed suicide. The associations are documented; the precise magnitudes are not.
‘Depression is inflammation’ holds for a subgroup of patients, not for everyone. Community-sample and twin data weaken the broader version of the claim.